Monopar Therapeutics Inc. (NASDAQ:MNPR) Secures $100M Financing And Accelerates Clinical Milestones
![]() |
Monopar enters an active near-term phase after a significant capital raise while clinical and regulatory catalysts approach; balance sheet strength supports further development even as short-term technical momentum softens. |









